MetaADEDB 2.0 @ LMMD
glycerol phenylbutyrate
(ZSDBFLMJVAGKOU-UHFFFAOYSA-N)
Structure
SMILES
O=C(OC(COC(=O)CCCc1ccccc1)COC(=O)CCCc1ccccc1)CCCc1ccccc1
Type(s)
Approved
ATC code(s)
A16AX09
Molecular Formula:
C33H38O6
Molecular Weight:
530.651
Log P:
6.0533
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
0
TPSA:
78.9
CAS Number(s):
611168-24-2
Synonym(s)
1.
glycerol phenylbutyrate
2.
HPN 100
3.
HPN-100
4.
HPN100
5.
Ravicti
External Link(s)
MeSHC570223
PubChem Compound10482134
ChEBI134745
CHEMBLCHEMBL2105745
DrugBankDB08909
DrugCentral4745
KEGGdr:D10127
Therapeutic Target DatabaseD0E0BD
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Ammonia increasedFAERS: 53
Canada Vigilance: 1
Canada Vigilance
US FAERS
2VomitingFAERS: 40US FAERS
3HeadacheFAERS: 20US FAERS
4MalaiseFAERS: 16US FAERS
5NauseaFAERS: 14US FAERS
6Drug dose omissionFAERS: 13US FAERS
7FatigueFAERS: 13US FAERS
8Hyperammonaemic crisisFAERS: 11US FAERS
9InfluenzaFAERS: 11US FAERS
10SomnolenceFAERS: 10US FAERS
11DizzinessFAERS: 8US FAERS
12NasopharyngitisFAERS: 8US FAERS
13LethargyFAERS: 7US FAERS
14DehydrationFAERS: 6US FAERS
15PneumoniaFAERS: 6US FAERS
16Amino acid level increasedFAERS: 5US FAERS
17Drug ineffectiveFAERS: 5
Canada Vigilance: 1
Canada Vigilance
US FAERS
18HypophagiaFAERS: 5US FAERS
19TremorFAERS: 5US FAERS
20Weight decreasedFAERS: 5US FAERS
21Amino acid level decreasedFAERS: 4US FAERS
22Ammonia abnormalFAERS: 4US FAERS
23AstheniaFAERS: 4US FAERS
24HypersensitivityFAERS: 4US FAERS
25Incorrect dose administeredFAERS: 4US FAERS
26Intentional product misuseFAERS: 4US FAERS
27Metabolic acidosisFAERS: 4US FAERS
28PancreatitisFAERS: 4US FAERS
29Altered state of consciousnessFAERS: 3US FAERS
30BronchitisFAERS: 3US FAERS
31Chest PainFAERS: 3US FAERS
32ConstipationFAERS: 3US FAERS
33Depressed moodFAERS: 3US FAERS
34Intentional product use issueFAERS: 3US FAERS
35PainFAERS: 3US FAERS
36RetchingFAERS: 3US FAERS
37ThirstFAERS: 3US FAERS
38TransplantFAERS: 3US FAERS
39Abdominal discomfortFAERS: 2US FAERS
40AnxietyFAERS: 2US FAERS
41Blood potassium decreasedFAERS: 2US FAERS
42Burning sensationFAERS: 2US FAERS
43ChillsFAERS: 2US FAERS
44CryingFAERS: 2US FAERS
45Diet refusalFAERS: 2US FAERS
46DroolingFAERS: 2US FAERS
47Drug effect incompleteFAERS: 2US FAERS
48EpistaxisFAERS: 2US FAERS
49Feeling abnormalFAERS: 2US FAERS
50GastroenteritisFAERS: 2US FAERS
51InfectionFAERS: 2US FAERS
52Joint injuryFAERS: 2US FAERS
53Memory impairmentFAERS: 2US FAERS
54Mental status changesFAERS: 2US FAERS
55NephrolithiasisFAERS: 2US FAERS
56No adverse eventFAERS: 2US FAERS
57Product dose omissionFAERS: 2US FAERS
58Product taste abnormalFAERS: 2US FAERS
59Respiratory FailureFAERS: 2US FAERS
60Unevaluable eventFAERS: 2US FAERS
61Urinary tract infectionFAERS: 2US FAERS
62Abdominal PainFAERS: 1US FAERS
63AcidosisFAERS: 1US FAERS
64AgitationFAERS: 1US FAERS
65AlopeciaFAERS: 1US FAERS
66AmnesiaFAERS: 1US FAERS
67Animal biteFAERS: 1US FAERS
68Ankle FractureFAERS: 1US FAERS
69AsthmaFAERS: 1US FAERS
70Atrial FibrillationFAERS: 1US FAERS
71Blood glucose increasedFAERS: 1US FAERS
72BradyphreniaFAERS: 1US FAERS
73Brain DeathFAERS: 1US FAERS
74CellulitisFAERS: 1US FAERS
75ClumsinessFAERS: 1US FAERS
76Croup infectiousFAERS: 1US FAERS
77Diastolic dysfunctionFAERS: 1US FAERS
78DisorientationFAERS: 1US FAERS
79Dry skinFAERS: 1US FAERS
80DysarthriaFAERS: 1US FAERS
81DysgeusiaFAERS: 1US FAERS
82DysuriaFAERS: 1US FAERS
83Emotional disorderFAERS: 1US FAERS
84Emotional distressFAERS: 1US FAERS
85Expired product administeredFAERS: 1US FAERS
86Eye inflammationFAERS: 1US FAERS
87Food AllergyFAERS: 1US FAERS
88Food cravingFAERS: 1US FAERS
89Gastric infectionFAERS: 1US FAERS
90Gastrointestinal PainFAERS: 1US FAERS
91Gastrointestinal bacterial overgrowthFAERS: 1US FAERS
92Gastrointestinal infectionFAERS: 1US FAERS
93Gastrostomy tube site complicationFAERS: 1US FAERS
94GastrostomyFAERS: 1US FAERS
95GingivitisFAERS: 1US FAERS
96GoutFAERS: 1US FAERS
97HungerFAERS: 1US FAERS
98HyperphagiaFAERS: 1US FAERS
99HypokinesiaFAERS: 1US FAERS
100HypoxiaFAERS: 1US FAERS
101HysterectomyFAERS: 1US FAERS
102Inappropriate schedule of drug administrationFAERS: 1US FAERS
103Inappropriate schedule of product administrationFAERS: 1US FAERS
104Incorrect product storageFAERS: 1US FAERS
105LacerationFAERS: 1US FAERS
106Limb operationFAERS: 1US FAERS
107Liquid product physical issueFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
108Liver scan abnormalFAERS: 1US FAERS
109MalabsorptionFAERS: 1US FAERS
110Malignant neoplasm progressionFAERS: 1US FAERS
111Maternal exposure during pregnancyFAERS: 1US FAERS
112Medical device site infectionFAERS: 1US FAERS
113Mesoblastic NephromaFAERS: 1US FAERS
114NocturiaFAERS: 1US FAERS
115Oncologic complicationFAERS: 1US FAERS
116PalpitationsFAERS: 1US FAERS
117Peripheral swellingFAERS: 1US FAERS
118Platelet count abnormalFAERS: 1US FAERS
119Portal HypertensionFAERS: 1US FAERS
120Product quality issueFAERS: 1US FAERS
121PruritusFAERS: 1US FAERS
122Psychiatric symptomFAERS: 1US FAERS
123Respiratory tract infection viralFAERS: 1US FAERS
124ScreamingFAERS: 1US FAERS
125Selective eating disorderFAERS: 1US FAERS
126SepsisFAERS: 1US FAERS
127Sinus TachycardiaFAERS: 1US FAERS
128SinusitisFAERS: 1US FAERS
129Slow speechFAERS: 1US FAERS
130StomatitisFAERS: 1US FAERS
131StressFAERS: 1US FAERS
132StridorFAERS: 1US FAERS
133SyncopeFAERS: 1US FAERS
134Throat irritationFAERS: 1US FAERS
135Tongue discomfortFAERS: 1US FAERS
136Tooth InfectionFAERS: 1US FAERS
137Urinary IncontinenceFAERS: 1US FAERS
138VertigoFAERS: 1US FAERS
139Visual ImpairmentFAERS: 1US FAERS
140Wrong technique in product usage processFAERS: 1US FAERS
141nervous system disorderFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.